Notícias

AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.

Boston Scientific has seen its share price fall sharply over the past year, which naturally raises a question for investors who care about fundamentals. Are the cash flows that the business can generate enough to support where the stock trades today, or has sentiment moved further than the underlying economics justify? The share price has declined 55.4% over the past year, so the recent slide puts the focus squarely on whether that move lines up with the cash that Boston Scientific can...

Investing.com -- Citi has downgraded Boston Scientific to Neutral from Buy, citing an uncertain recovery path after a string of setbacks this year.

Boston Scientific (NYSE:BSX) has initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and software over atrial fibrillation Burden Alert delays. The recall targets multiple versions of LUX-Dx hardware and associated software that may postpone detection alerts for atrial arrhythmias used in patient monitoring. The US FDA has taken enforcement interest in the action, underscoring regulatory scrutiny of the cardiac monitoring platform and its alert...

The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.

AGCO, BSX and BBWI have been added to the Zacks Rank #5 (Strong Sell) List on September 16th, 2026.

Boston Scientific Corporation (NYSE:BSX) fell 2.3% in early trading on September 8, 2026, after disclosing that an August 25 cyberattack disrupted manufacturing and shipping. The company stated it is unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. Though operations have since resumed, the incident […]

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th

(Updates with latest market prices and developments.) US benchmark equity indexes were lower intr

Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater

The medical device maker said it is unlikely to meet its full-year sales growth and adjusted earnings targets, and will update investors on Oct. 28

Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the St

Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.

In recent weeks, Boston Scientific has faced multiple voluntary global recalls of its Suture Cinch endoscopic devices and ENROUTE Transcarotid Neuroprotection systems, alongside a cybersecurity incident that disrupted operations and led to reduced full‑year 2026 sales and earnings guidance. These simultaneous product quality issues, operational disruptions, and softer demand for key franchises raise fresh questions about the resilience of Boston Scientific’s previously growth-focused...

Boston Scientific (BSX) is back in focus after a series of voluntary global recalls affecting its ENROUTE Transcarotid Neuroprotection Systems and OverStitch Suture Cinch devices, along with a separate cybersecurity incident that has disrupted operations and lowered 2026 guidance. Against this backdrop of recalls and a cybersecurity disruption, Boston Scientific’s recent share price performance has weakened. The stock is at US$48.37 with a year-to-date share price decline of 48.93%, alongside...

Boston Scientific (NYSE: BSX) has initiated multiple worldwide product recalls, including a Class I recall of its ENROUTE Transcarotid Neuroprotection System due to risks of arterial sheath tip separation. The company has also begun Class II recalls of certain OverStitch Suture Cinch endoscopic devices, citing deployment and suture cutting failures. These recalls affect widely distributed products and introduce added operational, regulatory and reputational pressures for Boston Scientific in...

Boston Scientific stock has had a steep year, with a sharp share price decline set against valuation checks that point to a potentially cheap entry point based on intrinsic value and market multiples. The stock now screens as undervalued on both a Discounted Cash Flow (DCF) view and on broader valuation metrics, which raises questions about how much of the recent operational setbacks the market has already priced in. Over the past 12 months, Boston Scientific shares have fallen about 55%,...

Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.

AU, APTV and BSX have been added to the Zacks Rank #5 (Strong Sell) List on August 28th, 2026.

On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the

The medical device specialist was the victim of a cyberattack.

Shares of medical-device maker Boston Scientific are down 4.5% Wednesday on concerns that a cyber-attack against the company could hurt near-term revenue. The incident, which Boston Scientific said it detected Tuesday, caused a network outage and disruption to operations, including the ability to process and ship orders, a spokeswoman said. Evercore ISI analysts noted that a similar cyberattack against medical-device maker Stryker in March took about three weeks for the company to recover from.

Boston Scientific stock falls as the medical device maker announces the latest batch of bad news for the company.

Boston Scientific (NYSE:BSX) disclosed on Tuesday that a cybersecurity incident has affected some of its information technology systems, disrupting parts of the medical device company’s operations. Shares of Boston Scientific fell 4% in premarket trading on Wednesday following the disclosure.

Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may be trading below what the fundamentals imply. That gap between weak recent returns and an undervalued read is now front of mind for anyone looking at the current US$51.83 share price. Over the last 12 months, Boston Scientific has declined 49.8%, which puts recent investor sentiment and the current...

Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air embolism risks. The recalls affect a broad mix of devices used in cardiac and vascular procedures across several international markets. Regulators and hospitals are assessing the implications for device safety protocols, clinical workflows, and future use of the impacted products. Product safety questions can prompt...

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c